Global Trial Shows Underestimation of Cardiovascular Risk in HIV Patients - Video

A new study has found that for people with HIV, current risk models underestimated cardiovascular events in both women and black men in high-income countries. Their findings are published in Lancet HIV. Researchers conducted a study to evaluate how well existing atherosclerotic cardiovascular disease risk estimates could be used to predict cardiovascular outcomes in global populations with HIV.

Their prospective cohort study used data from Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) to analyze individuals with HIV who were from low-, middle-, and high-income countries across several continents. The researchers found that for those in REPRIEVE, current risk models underestimated cardiovascular events in both women and black men in high income countries (HICs), while overestimating cardiovascular events for all people with HIV in low- and middle-income countries.

“These findings allow researchers to fine-tune cardiovascular disease prediction models for people living with HIV,” said Patrice Desvigne-Nickens, MD, a medical officer within the National Heart, Lung, and Blood Institute (NHLBI). “Assessing the accuracy of these predictions in subgroups of the population is possible because of carefully developed outreach and enrolling a diverse study population – representing all people at risk.”

Reference: Performance of the Pooled Cohorts Equations and D:A:D Risk Scores among Individuals with HIV in a Global Cardiovascular Disease Prevention Trial: A Cohort Study Leveraging Data from REPRIEVE